IRadimed Corporation develops, manufactures, and markets MRI-compatible medical devices, including IV infusion pump systems and patient vital signs monitoring systems. The company's primary products are the MRidium 3870 and 3860+ MRI-compatible IV infusion pump systems, which use non-magnetic ultrasonic motors to deliver fluids safely in high magnetic fields, and the IRadimed 3880 MRI-compatible patient vital signs monitoring system, which tracks ECG, SpO2, and other parameters during MRI procedures. IRadimed also produces the FMD1 3600 ferromagnetic detection device with TruSense threat qualification technology. The company sells directly to hospitals and acute care facilities in the United States and through independent distributors in international markets. Founded in 1992 as IRI Development, Inc., the company was reorganized as a Delaware corporation in 2014. Its founder, Roger Susi, previously developed the first MRI-compatible patient monitoring system in 1986 and the first non-magnetic MRI-compatible IV infusion pump in 2004.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage iradimed.com
Sector Healthcare IR page iradimed.com/investors/management
Tags
mri-compatible devices, iv infusion pumps, patient monitoring, ferromagnetic detection, non-magnetic technology, hospital equipment, MRidium 3870, MRidium 3860+, IRadimed 3880, FMD1 3600, TruSense, RALU, Masimo, IRadimed FMD
Press page iradimed.com/news

Metrics

Valuation  
Market cap $ 1.103B
Market cap (USD) $ 1.103B
P/E 46.11
PEG 2.24
P/BV 10.36
P/S 12.34
P/OCF 40.61
P/FCF 42.18
Dividend yield 0.01%
Turnover / mcap —
Returns  
ROE 24.8%
ROI 23.8%
ROIC 21.9%
Profit margin 26.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 20.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 83.814M 73.242M 65.562M 53.303M 41.815M 31.717M 38.517M 30.439M 23.082M 32.497M 31.594M 15.653M 11.34M
Net profit 22.48M 19.234M 17.193M 12.828M 9.325M 1.369M 9.631M 6.303M 499.764K 7.215M 7.53M 2.05M 1.937M
Free cash flow 17.182M 17.619M 6.025M 9.22M 10.776M 5.374M 9.864M 7.148M 2.64M 8.626M 7.351M 2.002M 1.311M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 97.28 55 47.47 28.29 46.2 22.8 23.38 24.46 15.15 11.1 28.02 12.9 —
Price performance 12m 0.77 0.16 0.68 -0.39 1.03 -0.02 -0.04 0.61 0.36 -0.6 1.17 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.78M 3.78M 4.21M 7.29M 4.57M 5.14M 13.3M 12.2M 10.6M 13.7M
↳ YoY growth -2.3% +0.1% +11.4% +73.2% -37.3% +12.3% +158.4% -7.9% -13.6% +29.5%
↳ 5y CAGR +16.3% +30.1% +3.4% +6.3% +28.6% +23.8% +7.7% +24.5%
Lease liabilities (USD) — — — 2.96M 2.72M 2.48M 2.21M 2.04M 154,688 —
Cash and deposits (USD) 17.7M 18.2M 28M 43.5M 50.1M 62M 58M 49.8M 52.2M 51.2M
Intangible assets (USD) 918,712 885,502 832,519 860,087 960,885 1.12M 2.07M 2.52M 3.1M 3.38M
Right-of-use assets (USD) — — — 2.96M 2.72M 2.48M 2.21M 2.04M 154,688 —
Cash flow detail
Operating cash flow (USD) 9.41M 3.42M 7.38M 10.2M 5.82M 11.3M 10M 13.5M 25.6M 24.9M
Purchases of property, plant and equipment (USD) -780,809 -775,574 -228,315 -368,281 -443,003 -482,325 -823,019 -7.44M -8.01M -7.77M
Change in receivables (cash effect) (USD) 75,297 -201,591 -446,896 -3.11M 2.69M -575,543 -8.24M 841,911 1.76M -3.03M
Change in inventories (cash effect) (USD) -1.48M -334,113 -121,591 123,680 -282,904 -393,316 -1.31M -7.47M 3.13M -1.38M
Change in payables (cash effect) (USD) 1,113 -523,449 34,161 149,319 -403,567 30,414 1.12M -216,436 -861,618 -76,000
Dividends paid (cash effect) (USD) — — — — — — -12.6M -13.2M -13.7M -15M
Share buybacks (cash effect) (USD) -9.97M -1.82M — — — — — — — —
Income taxes paid (cash effect) (USD) -3.39M -1.21M -1.38M -12,000 — -970,000 -1.71M -5.35M -6.51M -3.92M
Share-based compensation (USD) 1.84M 2.45M 1.76M 1.85M 3.96M 1.46M 1.39M 2.19M 2.52M 2.92M
Operating cash flow before change in receivables (USD) 9.33M 3.62M 7.82M 13.3M 3.13M 11.8M 18.3M 12.6M 23.9M 28M
Free cash flow (OCF - PPE - intangibles) (USD) 8.63M 2.64M 7.15M 9.86M 5.37M 10.8M 9.22M 6.02M 17.6M 17.2M
Income detail
Research and development expense (USD) 1.35M 1.72M 1.52M 1.43M 1.9M 1.91M 2.28M 2.86M 2.83M 2.98M
↳ 5y CAGR +8.5% +6.0% +1.5% +7.2% +5.7% +13.5% +14.6% +9.4%
Total comprehensive income (USD) 7.23M 487,704 6.32M 9.7M 1.38M 9.31M 12.8M 17.2M — —
Comprehensive income to owners (USD) 7.23M 487,704 6.32M 9.7M 1.38M 9.31M 12.8M 17.2M — —
Provision for credit losses (USD) 12,636 -7,083 15,833 31,338 27,884 13,876 102,767 208,337 -94,535 -84,000
Credit cost ratio (credit losses / average receivables) (%) 0.3% 0.2% 0.4% 0.5% 0.5% 0.3% 1.1% 1.6% 0.8% 0.7%
Reported Mar 10, 2017 Mar 8, 2018 Mar 7, 2019 Mar 6, 2020 Mar 5, 2021 Mar 4, 2022 Mar 2, 2023 Mar 1, 2024 Mar 6, 2025 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Announces Regular Quarterly Cash Dividend of $0.20 Per Share

•Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026.

•Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.

•Declares a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2026, payable on November 27, 2026.

Orlando, Florida, October 30, 2026 – IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.

Oct 30

Written By Kevin Jirka

  • Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026.

  • Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to  GAAP diluted EPS of  $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.

  • Declares a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2026, payable on November 27, 2026.

Download PDF

Orlando, Florida, October 30, 2026 – IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.

“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump.  As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our ‘quad stack’ configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and  standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year,” said Roger Susi, President and Chief Executive Officer of Iradimed.

“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61. We revise our guidance for the full-year 2026, expecting to report revenue of $91.6 million to $93.1 million from $91.0 million to $96.0 million, and GAAP diluted earnings per share to $1.90 to $1.94 from $1.90 to $2.05 and non-GAAP diluted earnings per share to $2.07 to $2.11 from $2.06 to $2.21,” added Mr. Susi.

The Company’s board of directors declared a regular quarterly cash dividend of $0.20 per share of our outstanding common stock. The dividend is payable to stockholders of record as of the close of business on November 13, 2026 and will be paid on November 27, 2026.

Three Months Ended September 30, 2026

For the three months ended September 30, 2026, the Company reported revenue of $24.2 million, compared to $21.2 million for the comparable period of 2025, which increased by $3.0 million or 14%. The Company reported net income of $6.5 million, compared to $5.6 million for the comparable period of 2025, which increased by 17%. Earnings per share increased by $0.08 per diluted share or 17% to $0.51 per diluted share, for the three months ended September 30, 2026, compared to $0.43 per diluted share for the same period of 2025.

For the three months ended September 30, 2026, non-GAAP net income was $7.1 million, an increase of 17% compared to $6.1 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $0.6 million for the third quarter of 2026 and $0.5 million for the third quarter of 2025. On a non-GAAP basis, net income per diluted share was $0.55 for the three months ended September 30, 2026, compared to $0.47 per diluted share for the comparable period of 2025, which increased by 17%.

Nine Months Ended September 30, 2026

For the nine months ended September 30, 2026, the Company reported revenue of $66.6 million, compared to $61.1 million for the comparable period of 2025, which increased by $5.5 million or 9%. The Company reported net income of $17.5 million, compared to $16.0 million for the comparable period of 2025, which increased by 9%. Earnings per share increased by $0.12 per diluted share or 10% to $1.37 per diluted share, for the nine months ended September 30, 2026, compared to $1.25 per diluted share for the same period of 2025.

For the nine months ended September 30, 2026, non-GAAP net income was $19.3 million, an increase of 9% compared to $17.8 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $1.8 million for each of the nine-month periods presented. On a non-GAAP basis, net income per diluted share was $1.50 for the nine months ended September 30, 2026, compared to $1.39 per diluted share for the comparable period of 2025, which increased by 8% .

Revenue Information:

For the three months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the three months ended September 30, 2026, the gross profit margin was 76% compared to 78% for the comparable period of 2025.

For the nine months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the nine months ended September 30, 2026, the gross profit margin was 76%  compared to 77% for the comparable period of 2025.

Cash Flow from Operations

For the three months ended September 30, 2026, cash flow from operations was $7.0 million, consistent with $7.0 million for the comparable period of 2025.  For the three months ended September 30, 2026, cash provided by operations reflected higher net income and a smaller increase in accounts receivable, partially offset by higher income tax payments, increased inventory purchases, and prepaid expenses.. See the compilation of non-GAAP free cash flow in the table later in this release.

For the nine months ended September 30, 2026, cash flow from operations was $21.2 million, compared to $19.0  million for the comparable period of 2025, an increase of 12%. For the nine months ended September 30, 2026, cash provided by operations reflected higher net income, a smaller increase in accounts receivable, and higher accounts payable, partially offset by higher income tax payments, increased inventory purchases, and a smaller increase in deferred revenue. See the compilation of non-GAAP free cash flow in the table later in this release.

Financial Guidance

For the fourth quarter of 2026, the Company expects revenue of $25.0 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, and non-GAAP diluted earnings per share of $0.57 to $0.61. For the full year 2026, the Company expects to report revenue of $91.6 million to $93.1 million, GAAP diluted earnings per share of $1.90 to $1.94, and non-GAAP diluted earnings per share of $2.07 to $2.11.

The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax expense. The Company expects stock-based compensation expense, net of tax, to be approximately $2.5 million and $0.6 million for the full year and third quarter of 2026, respectively.

Presentation of Amounts

Amounts discussed in this press release are presented in millions, rounded to one decimal place, and amounts in the accompanying financial tables are presented in thousands, except per share data. Percentage changes are calculated using the amounts in thousands presented in the tables, and per share amounts are calculated using unrounded amounts. As a result, percentages recalculated using the rounded amounts in millions may differ from those presented.

Use of Non-GAAP Financial Measures

We calculate non-GAAP net income as net income excluding:

  1. Stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period;

  2. Operating expenses, net of tax, that we believe are not indicative of the Company’s ongoing core operating performance; and

  3. Infrequent income tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes.

We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for the development of internal software and purchases of property and equipment.

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our stockholders through various means.

Our non-GAAP financial measures are important tools for financial and operational decision-making and for evaluating our ongoing core operating results.

A reconciliation of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of

operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with GAAP and are not indicative of net income or cash provided by operating activities.

Conference Call

The Company has scheduled a conference call to discuss this release beginning at 11:00 a.m. Eastern Time, October 30, 2026. Individuals interested in listening to the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7e9cb633a38e45258f691f2b6d592419

Once registered, a dial-in number, a unique PIN, and instructions will be provided to participants.

The conference call will also be available in real-time via the Internet at http://www.iradimed.com/en-us/investors/events/ . A recording of the call will be available on the Company’s website following the call's completion.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump systems (3860 and 3870) have a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solutions provide a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

To

Participate in

the 5th Annual

ROTH

Healthcare

Opportunities

Conference 

Sep 23

Written By Kevin Jirka

Orlando, Florida, September 23, 2026 – IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference. 

Iradimed’s CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 5th Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on September 29, 2026.

download pdf

Prompts

iRadimed Corporation (ticker IRMD), listed in United States.

ETFs Holding iRadimed Corporation

ETF Weight in ETF Shares Market value As of
SAWS 2.90% 2,497 $ 226.877K Jul 31, 2026
KNOW 0.79% 571 $ 54.565K Jun 30, 2026
SQLV 0.30% 902 $ 86.195K Jun 30, 2026
RUSC 0.20% 1,635 $ 156.241K Jun 30, 2026
FSEG 0.11% 64 $ 6,115.84 Jun 30, 2026
AVSC 0.05% 19,315 $ 1.639M Nov 16, 2026
FEAC 0.05% 127 $ 12.136K Jun 30, 2026
PSC 0.04% 9,838 $ 940.119K Jun 30, 2026
VFQY 0.04% 2,176 $ 187.963K Aug 31, 2026
RESM 0.04% 14 $ 1,337.84 Jun 30, 2026
DFAS 0.02% 95,525 $ 8.142M Nov 12, 2026
VFMO 0.02% 5,320 $ 459.542K Aug 31, 2026
FESM 0.01% 5,206 $ 497.485K Jun 30, 2026
MSSM 0.00% 341 $ 29.456K Aug 31, 2026
DFSU 0.00% 498 $ 42.445K Nov 12, 2026
DCOR 0.00% 9,227 $ 786.417K Nov 12, 2026
DFAC 0.00% 13,862 $ 1.181M Nov 12, 2026
DFAU 0.00% 1,919 $ 163.556K Nov 12, 2026
DFUS 0.00% 3,157 $ 269.071K Nov 12, 2026
EBI 0.00% 4 $ 345.52 Aug 31, 2026
AVUS 0.00% 1,823 $ 154.663K Nov 16, 2026
NTRL 0.00% 2,099 $ 0.00 Nov 16, 2026